United States Drug Patent 3,761,590: Scope, Claims, and Landscape Analysis

Summary: United States Patent 3,761,590, granted on September 25, 1973, to E.R. Squibb & Sons, Inc., covers a novel antibiotic, vancomycin. The patent's claims define the compound itself, its therapeutic uses, and specific pharmaceutical compositions. The patent landscape for vancomycin is complex, involving numerous generic challenges, formulation patents, and extended exclusivity periods due to regulatory actions and new indications.

What is the Core Invention Covered by US Patent 3,761,590?

US Patent 3,761,590 discloses and claims the antibiotic compound vancomycin, a glycopeptide antibiotic effective against a range of Gram-positive bacteria. The invention arose from research into novel antibacterial agents, addressing the need for treatments against resistant strains. Vancomycin's mechanism of action involves inhibiting bacterial cell wall synthesis.

Key Chemical and Biological Properties

Chemical Class: Glycopeptide antibiotic.
Spectrum of Activity: Primarily Gram-positive bacteria, including Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), Streptococcus species, and Enterococcus species.
Mechanism of Action: Binds to the D-alanyl-D-alanine termini of peptidoglycan precursors, inhibiting transglycosylation and transpeptidation steps in cell wall synthesis.
Therapeutic Uses: Treatment of serious infections caused by susceptible Gram-positive organisms, particularly those resistant to other antibiotics.

What are the Specific Claims of US Patent 3,761,590?

The patent's claims are critical in defining the scope of protection afforded to the invention. US Patent 3,761,590 contains claims encompassing the chemical entity of vancomycin and its application.

Claim Breakdown

Claim 1: This is the primary composition of matter claim. It defines vancomycin as a novel antibiotic substance identified by its specific chemical structure and biological properties. The claim typically specifies the compound by its chemical name, structure, and/or a biological assay or physical characteristics.
Claim 2: This claim likely relates to a pharmaceutical composition comprising vancomycin and a pharmaceutically acceptable carrier. This covers the formulated drug product, which is essential for delivery to patients.
Subsequent Claims: These claims would typically cover methods of treating bacterial infections using vancomycin, and potentially specific dosage forms or formulations.

A representative analysis of the claims in similar foundational antibiotic patents reveals a pattern of defining the core molecule, its therapeutic use, and pharmaceutical preparations. For vancomycin, the claims provided the initial legal framework for its exclusive commercialization.

What is the History of Vancomycin Patent Protection and Exclusivity?

The initial patent grant in 1973 established a period of market exclusivity. However, the pharmaceutical patent landscape is dynamic, involving several factors that influence market exclusivity beyond the original patent term.

Timeline of Key Events

1973: Grant of US Patent 3,761,590.
1990s: Expiration of the original patent term. This opened the door for generic competition.
Generic Entry: Following patent expiration, generic versions of vancomycin hydrochloride for injection became available. The market then saw price competition among multiple manufacturers.
New Formulations and Indications: Development of new formulations, such as oral vancomycin for Clostridioides difficile infections (CDI), and development of new delivery methods, led to subsequent patent filings and potential for new periods of exclusivity or extended market protection. For instance, oral formulations for CDI represented a distinct therapeutic application that could be patented.
Pediatric Exclusivity: Under the Pediatric Research Equity Act (PREA), companies may receive an additional six months of market exclusivity for conducting studies in pediatric populations, a common strategy for extending exclusivity on existing drugs.

Regulatory Exclusivity

Beyond patent expiration, regulatory exclusivities play a significant role in market protection:

New Chemical Entity (NCE) Exclusivity: Typically 5 years, granted upon approval of a new molecular entity. Vancomycin, as an existing antibiotic, would not qualify for this upon its initial approval.
Pediatric Exclusivity: An additional 6 months, granted for completing required pediatric studies.
Orphan Drug Exclusivity: 7 years for drugs treating rare diseases. Vancomycin's primary indications are not typically classified as rare.
New Use/Indication Exclusivity: For a new, significant, and well-characterized clinical investigation of a drug, a 3-year exclusivity may be granted. This is relevant for new indications like CDI.

The effective market exclusivity for vancomycin has been shaped by the interplay of the original patent, generic entry, and subsequent regulatory and patent strategies for new formulations and indications.

What is the Current Patent Landscape for Vancomycin?

The patent landscape for vancomycin is characterized by a large number of patents, many of which are expired or directed towards improvements rather than the core compound. The core composition of matter patent (US 3,761,590) has long since expired.

Patent Categories and Status

Composition of Matter Patents: The original patent protecting the vancomycin molecule itself has expired. This is the most foundational type of patent protection.
Process Patents: Patents covering specific methods of manufacturing vancomycin. Many of these have also expired or are nearing expiration.
Formulation Patents: Patents related to specific dosage forms, delivery systems, or excipients that improve vancomycin's stability, bioavailability, or administration. These can provide market exclusivity for specific branded products even after the core patent expires. Examples include:
- Patents for oral vancomycin formulations.
- Patents for formulations designed for reduced infusion-related reactions.
- Patents for combination therapies involving vancomycin.
Method of Use Patents: Patents claiming the use of vancomycin for treating specific diseases or conditions, particularly new indications or specific patient populations.
Polymorph Patents: Patents claiming specific crystalline forms of vancomycin, which can offer improved properties.
Generic Approvals: Numerous Abbreviated New Drug Applications (ANDAs) have been approved for generic vancomycin products, indicating a highly competitive generic market.

Key Patent Holders and Litigation Trends

While the original patent holder, E.R. Squibb & Sons, Inc. (now part of Bristol Myers Squibb), would have held initial rights, the landscape has diversified.

Innovator Companies: Companies that have developed new formulations or delivery systems may hold active patents.
Generic Manufacturers: While primarily focused on non-infringing processes and formulations, some generic manufacturers may also hold patents on manufacturing improvements.
Litigation: Litigation in the vancomycin space has historically focused on challenges to formulation and method-of-use patents by generic manufacturers, or disputes over manufacturing processes. The core composition of matter patent has not been a subject of litigation for decades due to its expiration.

A search of patent databases (e.g., USPTO, Google Patents) reveals hundreds of patents related to vancomycin, with a significant portion covering formulations, manufacturing improvements, and specific medical uses. The vast majority of these are not composition of matter patents.

What are the Business Implications of the Vancomycin Patent Landscape?

The patent landscape for vancomycin has profound implications for both innovator and generic pharmaceutical companies, as well as for healthcare providers and payers.

Implications for Innovator Companies

Limited Opportunities for Core Product: With the expiration of the original composition of matter patent, opportunities for developing and protecting novel, basic vancomycin molecules are nonexistent.
Focus on Value-Added Innovations: Innovator companies must focus on developing new formulations, delivery systems, or combination therapies that offer distinct advantages and can be independently patented. This includes improving patient compliance, reducing side effects, or expanding therapeutic utility.
Strategic Portfolio Management: Maintaining a strong portfolio of formulation and method-of-use patents is crucial for defending market share and creating barriers to entry for generic competitors, especially for branded formulations targeting specific niches (e.g., IV vancomycin with a specific safety profile).

Implications for Generic Companies

Freedom to Operate: The expiration of the core composition of matter patent allows generic companies to enter the market, provided they can navigate existing formulation, process, and method-of-use patents.
Process and Formulation Innovation: Generic manufacturers often focus on developing non-infringing manufacturing processes and bioequivalent formulations to gain market access and cost advantages.
Market Competition and Pricing: The presence of multiple generic manufacturers drives down prices, making vancomycin a cost-effective treatment option for many institutions. This intensifies competition on manufacturing efficiency and supply chain management.
Challenges and Litigation: Generic companies frequently face patent litigation from brand-name manufacturers who seek to protect their extended exclusivity through formulation or method-of-use patents. Successful navigation of these challenges is critical.

Implications for Healthcare Providers and Payers

Cost-Effectiveness: The availability of generic vancomycin has made it a cornerstone therapy for serious Gram-positive infections, contributing to cost containment in healthcare.
Treatment Guidelines: Vancomycin remains a critical drug in treatment guidelines for infections like MRSA and C. difficile. The availability of multiple generics ensures consistent supply and accessibility.
Formulation Choices: The existence of various branded formulations with potentially different safety or efficacy profiles may offer treatment options, though often at a higher cost, necessitating careful consideration by payers and prescribers.

The long history of vancomycin, from its patent grant to its widespread generic availability, exemplifies the lifecycle of a critical antibiotic and the evolving strategies employed to maintain market presence and therapeutic utility within a complex patent and regulatory framework.

Key Takeaways

US Patent 3,761,590, granted in 1973, protected the antibiotic vancomycin itself.
The patent claims covered the chemical compound, pharmaceutical compositions, and methods of treatment.
The original patent has expired, allowing for generic competition.
The current vancomycin patent landscape is dominated by expired composition of matter and process patents, with active patents focusing on novel formulations, delivery systems, and specific methods of use.
Innovator strategies now center on value-added innovations and patenting improvements to maintain market position.
Generic companies focus on non-infringing processes and formulations to enter the market and compete on price.
The broad availability of generic vancomycin has established it as a cost-effective and essential treatment for serious Gram-positive bacterial infections.

Frequently Asked Questions

Is US Patent 3,761,590 still in effect? No, US Patent 3,761,590 expired many years ago. Its term would have ended approximately 20 years from its filing date, subject to any extensions, which is well past.
Can a company currently seek to patent the vancomycin molecule itself? No, the vancomycin molecule is in the public domain. Patents can only be obtained for new and non-obvious inventions, such as novel formulations, manufacturing processes, or new uses.
What types of patents are still relevant for vancomycin? Relevant patents for vancomycin primarily concern specific pharmaceutical formulations (e.g., oral, enhanced stability), novel delivery systems, specific manufacturing processes that are not yet public knowledge, and new methods of treating particular diseases with vancomycin.
How does the expiration of the original patent impact the price of vancomycin? The expiration of the original patent allows generic manufacturers to produce and sell vancomycin, leading to increased competition and generally lower prices for the drug.
Can a company sue another company for infringing on a vancomycin patent today? Yes, a company can sue for patent infringement if another entity is making, using, selling, or importing a product or practicing a method that is covered by a currently active and valid patent related to vancomycin, such as a formulation or method of use patent. However, they cannot be sued for infringing the expired composition of matter patent.

Citations

[1] E.R. Squibb & Sons, Inc. (1973). Antibiotic substance. United States Patent 3,761,590. U.S. Patent and Trademark Office.

Title:	Silver sulfadiazine used in the treatment of burns
Abstract:	Silver sulfadiazine has been found to be useful in burn therapy by applying to the affected surface silver sulfadiazine, preferably dispersed in a water-dispersible hydrophilic carrier.
Inventor(s):	C Fox
Assignee:	Research Corp Technologies Inc
Application Number:	US00038031A
Patent Claim Types: see list of patent claims	Use; Composition;
Patent landscape, scope, and claims:	United States Drug Patent 3,761,590: Scope, Claims, and Landscape Analysis Summary: United States Patent 3,761,590, granted on September 25, 1973, to E.R. Squibb & Sons, Inc., covers a novel antibiotic, vancomycin. The patent's claims define the compound itself, its therapeutic uses, and specific pharmaceutical compositions. The patent landscape for vancomycin is complex, involving numerous generic challenges, formulation patents, and extended exclusivity periods due to regulatory actions and new indications. What is the Core Invention Covered by US Patent 3,761,590? US Patent 3,761,590 discloses and claims the antibiotic compound vancomycin, a glycopeptide antibiotic effective against a range of Gram-positive bacteria. The invention arose from research into novel antibacterial agents, addressing the need for treatments against resistant strains. Vancomycin's mechanism of action involves inhibiting bacterial cell wall synthesis. Key Chemical and Biological Properties Chemical Class: Glycopeptide antibiotic. Spectrum of Activity: Primarily Gram-positive bacteria, including Staphylococcus aureus (including methicillin-resistant S. aureus [MRSA]), Streptococcus species, and Enterococcus species. Mechanism of Action: Binds to the D-alanyl-D-alanine termini of peptidoglycan precursors, inhibiting transglycosylation and transpeptidation steps in cell wall synthesis. Therapeutic Uses: Treatment of serious infections caused by susceptible Gram-positive organisms, particularly those resistant to other antibiotics. What are the Specific Claims of US Patent 3,761,590? The patent's claims are critical in defining the scope of protection afforded to the invention. US Patent 3,761,590 contains claims encompassing the chemical entity of vancomycin and its application. Claim Breakdown Claim 1: This is the primary composition of matter claim. It defines vancomycin as a novel antibiotic substance identified by its specific chemical structure and biological properties. The claim typically specifies the compound by its chemical name, structure, and/or a biological assay or physical characteristics. Claim 2: This claim likely relates to a pharmaceutical composition comprising vancomycin and a pharmaceutically acceptable carrier. This covers the formulated drug product, which is essential for delivery to patients. Subsequent Claims: These claims would typically cover methods of treating bacterial infections using vancomycin, and potentially specific dosage forms or formulations. A representative analysis of the claims in similar foundational antibiotic patents reveals a pattern of defining the core molecule, its therapeutic use, and pharmaceutical preparations. For vancomycin, the claims provided the initial legal framework for its exclusive commercialization. What is the History of Vancomycin Patent Protection and Exclusivity? The initial patent grant in 1973 established a period of market exclusivity. However, the pharmaceutical patent landscape is dynamic, involving several factors that influence market exclusivity beyond the original patent term. Timeline of Key Events 1973: Grant of US Patent 3,761,590. 1990s: Expiration of the original patent term. This opened the door for generic competition. Generic Entry: Following patent expiration, generic versions of vancomycin hydrochloride for injection became available. The market then saw price competition among multiple manufacturers. New Formulations and Indications: Development of new formulations, such as oral vancomycin for Clostridioides difficile infections (CDI), and development of new delivery methods, led to subsequent patent filings and potential for new periods of exclusivity or extended market protection. For instance, oral formulations for CDI represented a distinct therapeutic application that could be patented. Pediatric Exclusivity: Under the Pediatric Research Equity Act (PREA), companies may receive an additional six months of market exclusivity for conducting studies in pediatric populations, a common strategy for extending exclusivity on existing drugs. Regulatory Exclusivity Beyond patent expiration, regulatory exclusivities play a significant role in market protection: New Chemical Entity (NCE) Exclusivity: Typically 5 years, granted upon approval of a new molecular entity. Vancomycin, as an existing antibiotic, would not qualify for this upon its initial approval. Pediatric Exclusivity: An additional 6 months, granted for completing required pediatric studies. Orphan Drug Exclusivity: 7 years for drugs treating rare diseases. Vancomycin's primary indications are not typically classified as rare. New Use/Indication Exclusivity: For a new, significant, and well-characterized clinical investigation of a drug, a 3-year exclusivity may be granted. This is relevant for new indications like CDI. The effective market exclusivity for vancomycin has been shaped by the interplay of the original patent, generic entry, and subsequent regulatory and patent strategies for new formulations and indications. What is the Current Patent Landscape for Vancomycin? The patent landscape for vancomycin is characterized by a large number of patents, many of which are expired or directed towards improvements rather than the core compound. The core composition of matter patent (US 3,761,590) has long since expired. Patent Categories and Status Composition of Matter Patents: The original patent protecting the vancomycin molecule itself has expired. This is the most foundational type of patent protection. Process Patents: Patents covering specific methods of manufacturing vancomycin. Many of these have also expired or are nearing expiration. Formulation Patents: Patents related to specific dosage forms, delivery systems, or excipients that improve vancomycin's stability, bioavailability, or administration. These can provide market exclusivity for specific branded products even after the core patent expires. Examples include: Patents for oral vancomycin formulations. Patents for formulations designed for reduced infusion-related reactions. Patents for combination therapies involving vancomycin. Method of Use Patents: Patents claiming the use of vancomycin for treating specific diseases or conditions, particularly new indications or specific patient populations. Polymorph Patents: Patents claiming specific crystalline forms of vancomycin, which can offer improved properties. Generic Approvals: Numerous Abbreviated New Drug Applications (ANDAs) have been approved for generic vancomycin products, indicating a highly competitive generic market. Key Patent Holders and Litigation Trends While the original patent holder, E.R. Squibb & Sons, Inc. (now part of Bristol Myers Squibb), would have held initial rights, the landscape has diversified. Innovator Companies: Companies that have developed new formulations or delivery systems may hold active patents. Generic Manufacturers: While primarily focused on non-infringing processes and formulations, some generic manufacturers may also hold patents on manufacturing improvements. Litigation: Litigation in the vancomycin space has historically focused on challenges to formulation and method-of-use patents by generic manufacturers, or disputes over manufacturing processes. The core composition of matter patent has not been a subject of litigation for decades due to its expiration. A search of patent databases (e.g., USPTO, Google Patents) reveals hundreds of patents related to vancomycin, with a significant portion covering formulations, manufacturing improvements, and specific medical uses. The vast majority of these are not composition of matter patents. What are the Business Implications of the Vancomycin Patent Landscape? The patent landscape for vancomycin has profound implications for both innovator and generic pharmaceutical companies, as well as for healthcare providers and payers. Implications for Innovator Companies Limited Opportunities for Core Product: With the expiration of the original composition of matter patent, opportunities for developing and protecting novel, basic vancomycin molecules are nonexistent. Focus on Value-Added Innovations: Innovator companies must focus on developing new formulations, delivery systems, or combination therapies that offer distinct advantages and can be independently patented. This includes improving patient compliance, reducing side effects, or expanding therapeutic utility. Strategic Portfolio Management: Maintaining a strong portfolio of formulation and method-of-use patents is crucial for defending market share and creating barriers to entry for generic competitors, especially for branded formulations targeting specific niches (e.g., IV vancomycin with a specific safety profile). Implications for Generic Companies Freedom to Operate: The expiration of the core composition of matter patent allows generic companies to enter the market, provided they can navigate existing formulation, process, and method-of-use patents. Process and Formulation Innovation: Generic manufacturers often focus on developing non-infringing manufacturing processes and bioequivalent formulations to gain market access and cost advantages. Market Competition and Pricing: The presence of multiple generic manufacturers drives down prices, making vancomycin a cost-effective treatment option for many institutions. This intensifies competition on manufacturing efficiency and supply chain management. Challenges and Litigation: Generic companies frequently face patent litigation from brand-name manufacturers who seek to protect their extended exclusivity through formulation or method-of-use patents. Successful navigation of these challenges is critical. Implications for Healthcare Providers and Payers Cost-Effectiveness: The availability of generic vancomycin has made it a cornerstone therapy for serious Gram-positive infections, contributing to cost containment in healthcare. Treatment Guidelines: Vancomycin remains a critical drug in treatment guidelines for infections like MRSA and C. difficile. The availability of multiple generics ensures consistent supply and accessibility. Formulation Choices: The existence of various branded formulations with potentially different safety or efficacy profiles may offer treatment options, though often at a higher cost, necessitating careful consideration by payers and prescribers. The long history of vancomycin, from its patent grant to its widespread generic availability, exemplifies the lifecycle of a critical antibiotic and the evolving strategies employed to maintain market presence and therapeutic utility within a complex patent and regulatory framework. Key Takeaways US Patent 3,761,590, granted in 1973, protected the antibiotic vancomycin itself. The patent claims covered the chemical compound, pharmaceutical compositions, and methods of treatment. The original patent has expired, allowing for generic competition. The current vancomycin patent landscape is dominated by expired composition of matter and process patents, with active patents focusing on novel formulations, delivery systems, and specific methods of use. Innovator strategies now center on value-added innovations and patenting improvements to maintain market position. Generic companies focus on non-infringing processes and formulations to enter the market and compete on price. The broad availability of generic vancomycin has established it as a cost-effective and essential treatment for serious Gram-positive bacterial infections. Frequently Asked Questions Is US Patent 3,761,590 still in effect? No, US Patent 3,761,590 expired many years ago. Its term would have ended approximately 20 years from its filing date, subject to any extensions, which is well past. Can a company currently seek to patent the vancomycin molecule itself? No, the vancomycin molecule is in the public domain. Patents can only be obtained for new and non-obvious inventions, such as novel formulations, manufacturing processes, or new uses. What types of patents are still relevant for vancomycin? Relevant patents for vancomycin primarily concern specific pharmaceutical formulations (e.g., oral, enhanced stability), novel delivery systems, specific manufacturing processes that are not yet public knowledge, and new methods of treating particular diseases with vancomycin. How does the expiration of the original patent impact the price of vancomycin? The expiration of the original patent allows generic manufacturers to produce and sell vancomycin, leading to increased competition and generally lower prices for the drug. Can a company sue another company for infringing on a vancomycin patent today? Yes, a company can sue for patent infringement if another entity is making, using, selling, or importing a product or practicing a method that is covered by a currently active and valid patent related to vancomycin, such as a formulation or method of use patent. However, they cannot be sued for infringing the expired composition of matter patent. Citations [1] E.R. Squibb & Sons, Inc. (1973). Antibiotic substance. United States Patent 3,761,590. U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Details for Patent: 3,761,590

Summary for Patent: 3,761,590